NEW YORK & CAMBRIDGE, Mass. — Blackstone has completed the final close of its latest life sciences fund at $6.3 billion, marking the largest private fund ever raised dedicated to the sector.
The fund, Blackstone Life Sciences VI, reached its hard cap and was oversubscribed, reflecting strong investor demand. The vehicle is nearly 40% larger than its predecessor.
Nicholas Galakatos, Ph.D., global head of Blackstone Life Sciences, said the close underscores continued confidence in the firm’s strategy and the broader life sciences market.
“We are grateful to the BXLS VI investors for their strong support of our strategies and the firm’s enduring conviction in the life sciences,” Galakatos said. “Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices. This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world.”
Blackstone launched its life sciences platform in 2018 to invest across the development cycle of drugs, devices, and other healthcare technologies. The platform had approximately $15 billion in assets under management as of the fourth quarter of 2025.
The firm said its investments have supported the development and commercialization of several major therapies and medical technologies, including LEQVIO, AMVUTTRA, and IMBRUVICA, as well as devices such as MiniMed Flex.
Blackstone also highlighted the platform’s performance, noting an 86% approval success rate for Phase III assets, exceeding industry averages.
Over the past year, Blackstone Life Sciences has committed nearly $2 billion in new investments. Recent transactions include funding agreements with Merck, Teva, and Alnylam, as well as a co-funding deal focused on acute myeloid leukemia and a transaction involving Anthos Therapeutics’ planned acquisition by Novartis.
The firm said the deals demonstrate its ability to source and finance large-scale investments in drug development and medical technology, positioning it as a major capital provider in the life sciences industry.
